Palvella Therapeutics, Inc (PVLA NASDAQ) stock market data APIs
$22.5574
-0.37(-1.6%)
as of June 30, 2025
Try our APIs with
free plan!
Palvella Therapeutics, Inc Financial Data Overview
Price chart is built with
Anychart
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania
Prev. Close
22.5574
Open
22.1875
High
22.8782
Low
21.965
52 wk Range
6.2-29.27
Market Cap
219 M
P/E Ratio
9.9239
Shares Outstanding
11 221 K
EPS
-0.7432
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Palvella Therapeutics, Inc data using free add-ons & libraries
Get Palvella Therapeutics, Inc Fundamental Data
Palvella Therapeutics, Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-15
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Palvella Therapeutics, Inc News
New
Palvella Therapeutics to join Russell 3000 and Russell 2000 Indexes
Palvella Therapeutics (NASDAQ:PVLA [https://seekingalpha.com/symbol/PVLA]) Monday said [https://seekingalpha.com/pr/20151515-palvella-therapeutics-added-to-russell-3000-and-russell-2000-indexes]that...
Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes
WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therap...
Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%
Enrollment of 51 subjects highlights significant unmet need in this serious, lifelong genetic disease which currently has no FDA-approved therapies Top-line data expected in the first quarter of 2026...
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1“20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors
New intellectual property builds on Palvella’s multi-layered exclusivity strategy Patent term expected through at least 2038 WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
